Related Experiment Video
Updated: Feb 13, 2026

In Vitro Thrombosis Test for Ventricular Assist Devices
Published on: March 21, 2025
Long-term follow-up evaluation of readmissions after ventricular assist device implantation: trends and outcomes
Mehmet Aksüt1, Mustafa Mert Özgür1, Hakan Hancer1
1Department of Cardiovascular Surgery, Kosuyolu High Specialization Research and Training Hospital, Istanbul, Türkiye.
Introduction:
With the increasing utilization of left ventricular assist devices (LVADs) as a pivotal treatment option for end-stage heart failure, the rehospitalization of patients equipped with these devices has emerged as a significant issue impacting both quality of life and healthcare costs. This study evaluates readmission trends, predisposing factors, and their effects on survival over a long-term follow-up period for patients undergoing LVAD implantation.
Methods:
The study included 141 patients who underwent LVAD implantation between 2015 and 2023 and were followed for a minimum of 12 months. We analyzed the reasons for readmission, trends related to the devices, and overall outcomes.
Results:
The median duration of LVAD support was 49 months (IQR: 22-60). Overall, 102 patients (72.3%) experienced at least one readmission, with a median of two readmissions per patient (IQR: 0-3). Patients who were readmitted had a significantly higher body mass index (median 26.3 kg/m2 vs. 23.4 kg/m2, p = 0.003). In the multivariable Cox regression analysis, right ventricular dysfunction was the only factor independently associated with hospital readmission (HR = 1.769, 95% CI: 1.097-2.854, p = 0.019). Other variables-including body mass index, reoperative surgery, male gender, and tricuspid valve intervention-were not significantly associated with readmission. The most frequent causes of readmission were wound or driveline infections (33.7%), arrhythmias (16.9%), and right ventricular failure (11.8%). Long-term survival did not differ significantly between readmitted and non-readmitted patients (p = 0.335). Among device types, HeartMate III demonstrated the best survival outcomes [median 60 (40-60) months].
Conclusion:
Although LVAD implantation substantially improves survival in advanced heart failure, hospital readmissions remain common throughout long-term follow-up. Right ventricular dysfunction represents a key determinant of readmission risk, highlighting the importance of optimized perioperative management and vigilant monitoring for right-sided failure. Preventive strategies aimed at early detection of RV dysfunction and driveline complications may further reduce rehospitalizations and improve patient outcomes.
Related Concept Videos
Current Trends in Nursing I
Current Trends in Nursing II
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
Predicting Reaction Outcomes
Outcomes of Glycolysis
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...
Long-term Depression

